Home » EMA Plan to Reassess Approved Pediatric Drugs Prompts Industry Pushback
EMA Plan to Reassess Approved Pediatric Drugs Prompts Industry Pushback
January 10, 2013
A European Medicines Agency draft guideline on pediatric drug development that requires regular reevaluations of approved drug products has prompted pushback from drugmakers, which see it as costly and retrospective.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor